Consensus for 2024 total revenue is $290.63M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DVAX:
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Dynavax initiated with a Neutral at Goldman Sachs
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Dynavax sees FY23 HEPLISAV-B vaccine net product revenue about $213M
- Dynavax sees Q4 HEPLISAV-B vaccine net product revenue about $51M